Sign InGreat-west Lifeco . Non-cum 1st Pfd Shs Series N Stock Earnings Reports
Buy GWO-PN
Great-West Lifeco . Non-Cum 1st Pfd Shs Series N Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $1.22 |
| EPS actual | $1.33 |
| EPS Surprise | 9.02% |
| Revenue estimate | 1.424B |
| Revenue actual | 1.424B |
| Release date | Aug 05, 2025 |
| EPS estimate | $1.17 |
| EPS actual | $0.99 |
| EPS Surprise | -15.04% |
| Revenue estimate | - |
| Revenue actual | 10.835B |
| Release date | May 07, 2025 |
| EPS estimate | $1.14 |
| EPS actual | $0.95 |
| EPS Surprise | -16.40% |
| Revenue estimate | - |
| Revenue actual | 11.016B |
| Release date | Feb 05, 2025 |
| EPS estimate | $1.14 |
| EPS actual | $1.23 |
| EPS Surprise | 7.89% |
| Revenue estimate | - |
| Revenue actual | -960000000 |
Last 4 Quarters for Great-West Lifeco . Non-Cum 1st Pfd Shs Series N
Below you can see how GWO-PN.TO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 05, 2025 |
| Price on release | $16.85 |
| EPS estimate | $1.14 |
| EPS actual | $1.23 |
| EPS surprise | 7.89% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $16.35 |
| Jan 31, 2025 | $16.47 |
| Feb 03, 2025 | $16.22 |
| Feb 04, 2025 | $16.70 |
| Feb 05, 2025 | $16.85 |
| Feb 06, 2025 | $16.35 |
| Feb 07, 2025 | $16.39 |
| Feb 10, 2025 | $16.43 |
| Feb 11, 2025 | $16.48 |
| 4 days before | 3.06% |
| 4 days after | -2.20% |
| On release day | -2.97% |
| Change in period | 0.795% |
| Release date | May 07, 2025 |
| Price on release | $15.32 |
| EPS estimate | $1.14 |
| EPS actual | $0.95 |
| EPS surprise | -16.40% |
| Date | Price |
|---|---|
| May 01, 2025 | $15.34 |
| May 02, 2025 | $15.34 |
| May 05, 2025 | $15.34 |
| May 06, 2025 | $15.34 |
| May 07, 2025 | $15.32 |
| May 08, 2025 | $15.32 |
| May 09, 2025 | $15.78 |
| May 12, 2025 | $15.85 |
| May 13, 2025 | $15.97 |
| 4 days before | -0.130% |
| 4 days after | 4.24% |
| On release day | 0% |
| Change in period | 4.11% |
| Release date | Aug 05, 2025 |
| Price on release | $18.40 |
| EPS estimate | $1.17 |
| EPS actual | $0.99 |
| EPS surprise | -15.04% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $18.32 |
| Jul 30, 2025 | $18.47 |
| Jul 31, 2025 | $18.48 |
| Aug 01, 2025 | $18.40 |
| Aug 05, 2025 | $18.40 |
| Aug 06, 2025 | $18.50 |
| Aug 07, 2025 | $18.34 |
| Aug 08, 2025 | $18.49 |
| Aug 11, 2025 | $18.34 |
| 4 days before | 0.437% |
| 4 days after | -0.326% |
| On release day | 0.543% |
| Change in period | 0.109% |
| Release date | Nov 05, 2025 |
| Price on release | $17.97 |
| EPS estimate | $1.22 |
| EPS actual | $1.33 |
| EPS surprise | 9.02% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $17.69 |
| Oct 31, 2025 | $17.83 |
| Nov 03, 2025 | $17.90 |
| Nov 04, 2025 | $17.80 |
| Nov 05, 2025 | $17.97 |
| Nov 06, 2025 | $17.80 |
| Nov 07, 2025 | $17.80 |
| Nov 10, 2025 | $17.79 |
| Nov 11, 2025 | $17.95 |
| 4 days before | 1.58% |
| 4 days after | -0.111% |
| On release day | -0.95% |
| Change in period | 1.47% |
Great-West Lifeco . Non-Cum 1st Pfd Shs Series N Earnings Call Transcript Summary of Q3 2025
Great-West Lifeco delivered a very strong Q3 2025 with record base earnings up 15% YoY and a base ROE of 17.7%. All four segments contributed to growth: Empower (U.S.) drove large net plan inflows (USD 30B) and Wealth net inflows (USD 3.4B), Canada showed mid-single-digit underlying growth with Group Benefits strength, Europe delivered double-digit constant-currency growth, and Capital & Risk Solutions (CRS) posted a 20% earnings increase largely from Capital Solutions transactions. Management raised the 2025 buyback target by $500M to $1.5B, citing robust cash flow and strong capital metrics (LICAT ~131%, leverage ~27%, $2.5B holdco cash). Insurance experience was unusually favorable this quarter (mortality gains), and management expects continued volatility in experience items. CRS is a strategic growth engine: management expects mid-single-digit (or better) medium-term earnings growth for CRS but will remain disciplined and selective on new business to protect ROEs. Management highlighted ongoing technology and AI investments (productivity lifts in app development and customer service) that should sustain and further improve margins, especially at Empower, and reiterated that organic growth can meet medium-term ambitions while keeping M&A optional and disciplined.
